11/18
06:19 am
hura
HURA: Third Quarter Results [Yahoo! Finance]
Medium
Report
HURA: Third Quarter Results [Yahoo! Finance]
11/17
07:56 am
hura
TuHURA Biosciences: Potential In Immunotherapy Resistance, But How Will It Be Funded? [Seeking Alpha]
High
Report
TuHURA Biosciences: Potential In Immunotherapy Resistance, But How Will It Be Funded? [Seeking Alpha]
11/14
02:39 pm
hura
TuHURA Biosciences (NASDAQ:HURA) had its price target lowered by analysts at Maxim Group from $15.00 to $8.00. They now have a "buy" rating on the stock.
Medium
Report
TuHURA Biosciences (NASDAQ:HURA) had its price target lowered by analysts at Maxim Group from $15.00 to $8.00. They now have a "buy" rating on the stock.
11/14
07:16 am
hura
TuHURA Biosciences, Inc. Reports Third Quarter 2025 Financial Results and Provides a Corporate Update [Yahoo! Finance]
Low
Report
TuHURA Biosciences, Inc. Reports Third Quarter 2025 Financial Results and Provides a Corporate Update [Yahoo! Finance]
11/14
07:00 am
hura
TuHURA Biosciences, Inc. Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
Low
Report
TuHURA Biosciences, Inc. Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
11/3
09:01 am
hura
TuHURA Biosciences Discovery Research on Targeting the Delta Opioid Receptor (DOR) to Reprogram Myeloid-Derived Suppressor Cells (MDSCs) Selected for Oral Presentation at the 67th ASH Annual Meeting and Exposition
Medium
Report
TuHURA Biosciences Discovery Research on Targeting the Delta Opioid Receptor (DOR) to Reprogram Myeloid-Derived Suppressor Cells (MDSCs) Selected for Oral Presentation at the 67th ASH Annual Meeting and Exposition
10/25
12:13 pm
hura
TuHURA Biosciences (NASDAQ:HURA) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
TuHURA Biosciences (NASDAQ:HURA) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.